查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1618713

多重诊断市场：按方法、应用和最终用户划分 - 全球预测 2025-2030

Multiplexed Diagnostics Market by Method (High Density Multiplexed Assays, Low Density Multiplexed Assays, Mid-Density Multiplexed Assays), Application (Allergic Diseases, Autoimmune Diseases, Cardiology), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，多重诊断市值为149.8亿美元，预计到2024年将达到173.6亿美元，复合年增长率为16.62%，预计到2030年将达到439.7亿美元。

多重诊断可在一次测试中同时检测和分析多种生物标记或分析物，为提高医疗应用中的诊断准确性和效率提供了巨大潜力。对多重诊断的需求源于对全面、快速诊断解决方案日益增长的需求，这对于癌症、感染疾病和慢性病等复杂疾病的管理至关重要。这些诊断广泛应用于实验室、临床环境和研究机构，涵盖从疾病筛检到个人化医疗的各个领域。最终用途领域主要包括医疗保健提供者、学术研究、製药和生技公司。根据市场洞察，多重诊断市场的成长受到技术进步、慢性病盛行率上升以及对具有成本效益和高效的诊断解决方案不断增长的需求的显着影响。此外，基因组学和蛋白​​质组学的进步，以及人工智慧和机器学习的整合，正在提供有希望的机会。公司可以透过专注于开发易于使用的平台并结合奈米技术和生物资讯学等尖端技术来抓住这些机会。然而，高昂的初始成本、复杂的监管要求以及需要熟练人员操作先进诊断工具等挑战正在阻碍市场成长。另一个挑战是该领域技术变革的快速步伐，需要不断创新和适应。创新和研究的最佳领域是开发更强大、更通用的多重平台、照护现场诊断以及在资源匮乏环境中使用的增强功能。投资于提高敏感性和特异性、同时降低成本和改善患者治疗效果的研究可以推动业务成长。整体而言，市场动态的本质是动态和竞争的，凸显了策略伙伴关係和对最尖端科技的投资对于获得产业优势的重要性。

主要市场统计
基准年[2023] 149.8亿美元
预计年份 [2024] 173.6亿美元
预测年份 [2030] 439.7亿美元
复合年增长率（%） 16.62%

市场动态：快速发展的多重诊断市场的关键市场洞察

供给和需求的动态交互作用正在改变多重诊断市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 癌症和其他感染疾病的流行
    • 增加基因组学和个人化医疗的私人和公共资金
    • 自动化设备和分析系统的需求
  • 市场限制因素
    • 有限的多重水平和单一检测位点之间潜在的交叉敏感性
  • 市场机会
    • 新型高阶多重诊断工具简介
    • 日益关注次世代定序解决方案的研发
  • 市场挑战
    • 缺乏接受过处理多重诊断设备培训的医疗保健专业人员

波特五力：驾驭多重诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解多重诊断市场的外部影响

外部宏观环境因素在塑造多重诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解多重诊断市场的竞争状况

对多重诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵多重诊断市场供应商绩效评估

FPNV 定位矩阵是评估多重诊断市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘多重诊断市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，多重诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症和其他感染疾病的传播
      • 增加基因组学和个人化医疗的公共和私人资金
      • 对自动化设备和分析系统的需求
    • 抑制因素
      • 多重检测水平有限，单一检测位点之间可能发生交叉敏感性
    • 机会
      • 介绍新型先进的多重诊断工具
      • 专注于研发活动，打造次世代定序解决方案
    • 任务
      • 缺乏接受过处理多种诊断设备训练的医疗保健专业人员
  • 市场区隔分析
    • 方法：高密度多重检测的使用由于其诊断准确性高而不断增加
    • 应用：多重诊断在肿瘤疾病检测的指数应用
    • 最终用户：医院需要使用多重诊断进行先进的高通量筛检
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章多重诊断市场：依方法

  • 高密度多重侦测
  • 低密度多重侦测
  • 中密度多重检测
  • 超高密度多重侦测

第七章多重诊断市场：按应用

  • 过敏性疾病
  • 自体免疫疾病
  • 心臟病学
  • 感染疾病
  • 肿瘤学

第 8 章 多重诊断市场：依最终使用者分类

  • 学术研究
  • 临床调查
  • 诊断实验室
  • 医院
  • 製药公司

第九章北美和南美的多重诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区多重诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲多重诊断试剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争场景分析
    • Nanopin 推出以血液为基础的结核病检测，为多重 HIV/TB 检测奠定基础
    • ChromaCode 与 Protean BioDiagnostics 建立策略伙伴关係，在美国推出基于 HDPCR 的 NSCLC 检测
    • EDP​​ 生物技术宣布与 New Day Diagnostics 合併
    • Delta Diagnostics 在 A 轮资金筹措中筹集了 525 万欧元（576 万美元），以革新生物感测技术
    • ChromaCode 宣布与 MedGenome 合作，将基于 HDPCR 的诊断引入印度和中东
    • Aptitude 与 BARDA 签署价值高达 5,400 万美元的合作协议，开始开发用于照护现场和家庭使用的诊断技术
    • Proxim Diagnostics 宣布获得生物梅里埃的策略投资
    • 合成生物学Start-UpsD-Nome 从 Ankur Capital、Campus Fund 筹集 150 万美元资金
    • ALiA BioTech 的一站式诊断平台将多重检测带入医学前沿
    • 安捷伦和 Akoya Biosciences 宣布合作推动生物製药应用多重组织检测开发
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • Agilent Technologies, Inc.
  • Akoya Biosciences
  • AusDiagnostics by R-Biopharm
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cardinal Health
  • Chembio
  • ChromaCode, Inc.
  • Danaher Corporation
  • Delta Diagnostics BV
  • F. Hoffmann-La Roche AG
  • Genabio Diagnostics Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Leica Biosystems
  • Medtronic PLC
  • Merck KGaA
  • NanoPin Technologies
  • Novartis AG
  • PCR Biosystems
  • QIAGEN NV
  • Quansys Biosciences Inc.
  • Seegene, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.
  • West Pharmaceutical Services
Product Code: MRR-036C5CF3A8A5

The Multiplexed Diagnostics Market was valued at USD 14.98 billion in 2023, expected to reach USD 17.36 billion in 2024, and is projected to grow at a CAGR of 16.62%, to USD 43.97 billion by 2030.

Multiplexed diagnostics involves the simultaneous detection and analysis of multiple biomarkers or analytes in a single test, offering vast potential in enhancing diagnostic accuracy and efficiency in medical applications. The necessity for multiplexed diagnostics arises from the evolving needs for comprehensive and rapid diagnostic solutions, which are essential in managing complex diseases such as cancer, infectious diseases, and chronic conditions. These diagnostics are employed extensively in laboratories, clinical settings, and research institutions for applications ranging from disease screening to personalized medicine. The end-use sectors primarily include healthcare providers, academic research, pharmaceuticals, and biotechnology firms. Market insights indicate that the growth of the multiplexed diagnostics market is significantly influenced by technological advancements, the rising prevalence of chronic diseases, and an increasing demand for cost-effective and efficient diagnostic solutions. Furthermore, advancements in genomics and proteomics, along with the integration of artificial intelligence and machine learning, present promising opportunities. Companies can seize these opportunities by focusing on developing user-friendly platforms and incorporating advanced technologies such as nanotechnology and bioinformatics. However, market growth is challenged by factors such as high initial costs, complex regulatory requirements, and the need for highly skilled personnel to operate sophisticated diagnostic tools. The fast-paced nature of technological change in the field also poses a challenge, requiring continuous innovation and adaptation. The best areas of innovation and research lie in the development of more robust and versatile multiplexing platforms, point-of-care diagnostics, and scaling up capabilities for use in low-resource settings. Investing in research that enhances sensitivity and specificity while reducing costs and improving patient outcomes can drive business growth. Overall, the nature of the multiplexed diagnostics market is dynamic and competitive, emphasizing the importance of strategic partnerships and investments in cutting-edge technologies to stay ahead in the industry.

KEY MARKET STATISTICS
Base Year [2023] USD 14.98 billion
Estimated Year [2024] USD 17.36 billion
Forecast Year [2030] USD 43.97 billion
CAGR (%) 16.62%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multiplexed Diagnostics Market

The Multiplexed Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of cancers and other infectious diseases
    • Rise in private-public funding for genomics & personalized medicine
    • Demand for automated equipment & analytical systems
  • Market Restraints
    • Limited multiplexing levels and possible cross-sensitivity between single detection sites
  • Market Opportunities
    • Introduction of new and advanced multiplexed diagnostic tools
    • Increasing emphasis on R&D activities to generate next-generation sequencing solutions
  • Market Challenges
    • Lack of trained healthcare professionals for handling multiplexed diagnostic equipment

Porter's Five Forces: A Strategic Tool for Navigating the Multiplexed Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multiplexed Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multiplexed Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multiplexed Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multiplexed Diagnostics Market

A detailed market share analysis in the Multiplexed Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multiplexed Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multiplexed Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Multiplexed Diagnostics Market

A strategic analysis of the Multiplexed Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Multiplexed Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AccuBioTech Co., Ltd., Agilent Technologies, Inc., Akoya Biosciences, AusDiagnostics by R-Biopharm, Baxter International Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardinal Health, Chembio, ChromaCode, Inc., Danaher Corporation, Delta Diagnostics BV, F. Hoffmann-La Roche AG, Genabio Diagnostics Inc., Hologic, Inc., Illumina, Inc., Leica Biosystems, Medtronic PLC, Merck KGaA, NanoPin Technologies, Novartis AG, PCR Biosystems, QIAGEN N.V., Quansys Biosciences Inc., Seegene, Inc., Siemens Healthineers, Thermo Fisher Scientific, Inc., and West Pharmaceutical Services.

Market Segmentation & Coverage

This research report categorizes the Multiplexed Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Method, market is studied across High Density Multiplexed Assays, Low Density Multiplexed Assays, Mid-Density Multiplexed Assays, and Very High Density Multiplexed Assays.
  • Based on Application, market is studied across Allergic Diseases, Autoimmune Diseases, Cardiology, Infectious Diseases, and Oncology.
  • Based on End-User, market is studied across Academic Research, Clinical Research, Diagnostic Labs, Hospitals, and Pharma Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cancers and other infectious diseases
      • 5.1.1.2. Rise in private-public funding for genomics & personalized medicine
      • 5.1.1.3. Demand for automated equipment & analytical systems
    • 5.1.2. Restraints
      • 5.1.2.1. Limited multiplexing levels and possible cross-sensitivity between single detection sites
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new and advanced multiplexed diagnostic tools
      • 5.1.3.2. Increasing emphasis on R&D activities to generate next-generation sequencing solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of trained healthcare professionals for handling multiplexed diagnostic equipment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Method: Increased use of high-density multiplexed assays owing to their high precision in diagnostics
    • 5.2.2. Application: Exponential use of multiplexed diagnostics for oncology disease detection
    • 5.2.3. End-User: Need for advanced and high-throughput screening with multiplexed diagnostics in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Multiplexed Diagnostics Market, by Method

  • 6.1. Introduction
  • 6.2. High Density Multiplexed Assays
  • 6.3. Low Density Multiplexed Assays
  • 6.4. Mid-Density Multiplexed Assays
  • 6.5. Very High Density Multiplexed Assays

7. Multiplexed Diagnostics Market, by Application

  • 7.1. Introduction
  • 7.2. Allergic Diseases
  • 7.3. Autoimmune Diseases
  • 7.4. Cardiology
  • 7.5. Infectious Diseases
  • 7.6. Oncology

8. Multiplexed Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic Research
  • 8.3. Clinical Research
  • 8.4. Diagnostic Labs
  • 8.5. Hospitals
  • 8.6. Pharma Companies

9. Americas Multiplexed Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Multiplexed Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Multiplexed Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. NanoPin Launches Blood-Based TB Test, Lays Groundwork for Multiplex HIV/TB Testing
    • 12.3.2. ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the United States
    • 12.3.3. EDP Biotech Announces Merger with New Day Diagnostics
    • 12.3.4. Delta Diagnostics raises EUR 5.25 million (USD 5.76 million) in Series A Funding to Revolutionize Biosensing Technology
    • 12.3.5. ChromaCode Announces Partnership with MedGenome to Bring HDPCR-based Diagnostics to India and the Middle East
    • 12.3.6. Aptitude Receives up to USD 54 Million Partnership with BARDA to Develop Diagnostics for Point-of-Care and At-Home Use
    • 12.3.7. Proxim Diagnostics Announces Strategic Investment from bioMerieux
    • 12.3.8. Synthetic biology startup D-Nome raises USD 1.5 million in funding from Ankur Capital, Campus Fund
    • 12.3.9. ALiA BioTech's One-stop Diagnostic Platform Brings Multiplex Testing to the Medical Front Line
    • 12.3.10. Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AccuBioTech Co., Ltd.
  • 3. Agilent Technologies, Inc.
  • 4. Akoya Biosciences
  • 5. AusDiagnostics by R-Biopharm
  • 6. Baxter International Inc.
  • 7. Becton, Dickinson and Company
  • 8. Bio-Rad Laboratories, Inc.
  • 9. bioMerieux SA
  • 10. Cardinal Health
  • 11. Chembio
  • 12. ChromaCode, Inc.
  • 13. Danaher Corporation
  • 14. Delta Diagnostics BV
  • 15. F. Hoffmann-La Roche AG
  • 16. Genabio Diagnostics Inc.
  • 17. Hologic, Inc.
  • 18. Illumina, Inc.
  • 19. Leica Biosystems
  • 20. Medtronic PLC
  • 21. Merck KGaA
  • 22. NanoPin Technologies
  • 23. Novartis AG
  • 24. PCR Biosystems
  • 25. QIAGEN N.V.
  • 26. Quansys Biosciences Inc.
  • 27. Seegene, Inc.
  • 28. Siemens Healthineers
  • 29. Thermo Fisher Scientific, Inc.
  • 30. West Pharmaceutical Services

LIST OF FIGURES

  • FIGURE 1. MULTIPLEXED DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MULTIPLEXED DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MULTIPLEXED DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MULTIPLEXED DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MULTIPLEXED DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY LOW DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY MID-DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY VERY HIGH DENSITY MULTIPLEXED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ALLERGIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY PHARMA COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM MULTIPLEXED DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. MULTIPLEXED DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. MULTIPLEXED DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023